|
| First author, year | Gender | Country | Patients () | Control group | Study group | Period (day) | Follow-up (day) |
|
| Hirakauva et al. [19], 2017 | F | Brazil | 217 | Placebo qd () | Levofloxacin 500 mg qd (), sulfamethoxazole 400 mg-trimethoprim 80 mg qd (), or nitrofurantoin 100 mg qd () | 1 d | 14 d |
| Rahardjo et al. [17], 2016 | F/M | Indonesia | 126 | Placebo qd () | Levofloxacin 500 mg qd () | 3 d | 4 d |
| Gürbüz et al. [20], 2013 | F/M | Turkey | 411 | Blank control () | Ciprofloxacin 500 mg qd (), or fosfomycin trometamol unknown dose qd () | 1 d | 5-7 d |
| Siracusano et al. [26], 2008 | F | Italy | 262 | Placebo qd () | Norfloxacin 400 mg qd () | 1 d | 3 d |
| Realfonso et al. [27], 2008 | F | Italy | 70 | Placebo qd ()/blank control () | Levofloxacin 500 mg qd () | 1 d | 7 d |
| Kartal et al. [28], 2006 | F/M | Turkey | 192 | Blank control () | Ciprofloxacin 500 mg qd () | 1 d | 2-3 d |
| Yip et al. [29], 2006 | F | Hong Kong | 130 | Placebo () | Amoxicillin 250 mg-clavulanic acid 125 mg qd () | 1 d | 2 d |
| Peschers et al. [30], 2001 | F | Germany | 70 | Placebo () | Trimethoprim 320 mg-sulfamethoxazole 1600 mg qd () | 1 d | 14 d |
| Darouiche et al. [16], 1994 | F/M | USA | 40 | Placebo qd () | Ciprofloxacin 500 mg bid () | 2 d | 3-5 d |
| Baker et al. [14], 1991 | F | Canada | 102 | Finapyridine 200 mg tid (); | Nitrofurantoin 50 mg q6h-finapyridine 200 mg tid () | 1 d | 2-3 d |
| Coptcoat et al. [15], 1988 | F/M | British | 82 | Blank control () | Trimethoprim 200 mg qd () | 1 d | 2 d |
| Tosto et al. [13], 1989 | F | Italy | 31 | Blank control () | Cinoxacin 500 mg bid () | 5 d | 3-7 d |
| Bergman and McCarthy [9], 1983 | F | USA | 96 | Finapyridine 100 mg tid () | Nitrofurantoin 50 mg-finapyridine 100 mg tid () | 3 d | 7 d |
|
